Hookipa Pharma announced plans to delist from Nasdaq and fully liquidate following the sale of its key vaccine assets to Gilead and the cancellation of a merger with Poolbeg Pharma. With no remaining revenue-generating products and halted clinical development on notable immunotherapies, the company’s board concluded winding down offers greater shareholder value than continued operations after a difficult period including collaboration setbacks and layoffs.